Galactomannan antigen (GM) testing has been used for decades to screen immunocompromised patients for invasive aspergillosis (IA). Recent publications suggested that using a higher cut-off value than 0.5 in bronchoalveolar lavage fluid (BALF) could be more discriminant for hematology patients. We retrospectively analyzed the values of GM in BALF over 7 years (from 2010 to 2016). Performance indicators of the GM in BALF, according to three different cut-off values (0.5, 0.8, 1.5), were calculated using Stata 14.1. IA classification for hematology patients was based on European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria, as defined in 2008. A number of 716 GM were performed on BALF from 2010 to 2016 (597 patients) and 66 were positive (> 0.5). Among these 597 patients, 27 IA were diagnosed, 13 with a positive GM in BALF, 9 with a negative GM in BALF, and 5 unclassified IA (ICU patients). The analysis of performance indicators, based on our local data, did not demonstrate any significant difference using a higher cut-off value of GM in BALF. This result may be explained by the local recruitment of patients and by pre-analytic variations during BALF realization.

Chrono Environnement CNRS 6249 Research Team Franche Comté University Besançon France

Department of Parasitology Mycology Besançon University Hospital Besançon France

Infection Control Department Besançon University Hospital Besançon France

Intensive Care Hematology Unit Besançon University Hospital Besançon France

Zobrazit více v PubMed

Clin Infect Dis. 2008 Jun 15;46(12):1813-21 PubMed

F1000Res. 2017 Feb 17;6: PubMed

J Infect. 2016 Jun;72(6):738-744 PubMed

Med Mycol. 2015 Sep;53(7):760-4 PubMed

J Clin Microbiol. 2005 Oct;43(10):5097-101 PubMed

Diagn Microbiol Infect Dis. 2014 Jul;79(3):322-7 PubMed

Clin Chem. 2009 Apr;55(4):611-22 PubMed

Crit Care. 2016 May 10;20(1):139 PubMed

Crit Rev Microbiol. 2015 Feb;41(1):124-34 PubMed

J Clin Microbiol. 2012 Mar;50(3):823-30 PubMed